Pregnane X receptor (PXR/NR1I2) gene haplotypes modulate susceptibility to inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 17, Issue 9, 2011, Pages 1917-1924

  Glas, Jürgen ^a,b   Seiderer, Julia ^b   Fischer, Daniel ^b   Tengler, Barbara ^b   Pfennig, Simone ^b   Wetzke, Martin ^c   Beigel, Florian ^b   Olszak, Torsten ^b   Weidinger, Maria ^b   Göke, Burkhard ^b   Ochsenkühn, Thomas ^b   Folwaczny, Matthias ^e   Müller Myhsok, Bertram ^d   Diegelmann, Julia ^b   Czamara, Darina ^d   Brand, Stephan ^b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^e NONE

Author keywords

Crohn's disease; CYP3A4; genetics; haplotypes; inflammatory bowel disease; MDR1; polymorphism; pregnane X receptor; PXR; PXR NR1I2; ulcerative colitis

Indexed keywords

ARGININE; GENOMIC DNA; GLYCINE; PREGNANE X RECEPTOR;

ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CAUCASIAN; CHILD; COLON CROHN DISEASE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; DNA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, STEROID; YOUNG ADULT;

EID: 80051516622     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21562     Document Type: Article

References (42)

1. Weersma RK, van Dullemen HM, van der Steege G, et al. Review article: Inflammatory bowel disease and genetics. Aliment Pharmacol Ther. 2007; 26 (suppl 2): 57-65. (Pubitemid 350233321)
2. Xavier RJ, Podolsky DK,. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007; 448: 427-434. (Pubitemid 47123518)
3. Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007; 39: 207-211. (Pubitemid 46184351)
4. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006; 314: 1461-1463. (Pubitemid 44871953)
5. Brand S,. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut. 2009; 58: 1152-1167.
6. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411: 599-603. (Pubitemid 32531408)
7. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001; 411: 603-606. (Pubitemid 32531409)
8. Schnitzler F, Brand S, Staudinger T, et al. Eight novel CARD15 variants detected by DNA sequence analysis of the CARD15 gene in 111 patients with inflammatory bowel disease. Immunogenetics. 2006; 58: 99-106.
9. Seiderer J, Brand S, Herrmann KA, et al. Predictive value of the CARD15 variant 1007fs for the diagnosis of intestinal stenoses and the need for surgery in Crohn's disease in clinical practice: results of a prospective study. Inflamm Bowel Dis. 2006; 12: 1114-1121. (Pubitemid 44847468)
10. Brand S, Staudinger T, Schnitzler F, et al. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm Bowel Dis. 2005; 11: 645-652. (Pubitemid 40965520)
11. Brand S, Hofbauer K, Dambacher J, et al. Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease phenotype. Am J Gastroenterol. 2006; 101: 99-106. (Pubitemid 43381715)
12. Glas J, Seiderer J, Wetzke M, et al. rs1004819 is the main disease-associated IL23R variant in German Crohn's disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants. PLoS ONE. 2007; 2: e819.
13. Glas J, Konrad A, Schmechel S, et al. The ATG16L1 gene variants rs2241879 and rs2241880 (T300A) are strongly associated with susceptibility to Crohn's disease in the German population. Am J Gastroenterol. 2008; 103: 682-691. (Pubitemid 351406000)
14. Langmann T, Moehle C, Mauerer R, et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology. 2004; 127: 26-40. (Pubitemid 38962271)
15. Matic M, Mahns A, Tsoli M, et al. Pregnane X receptor: promiscuous regulator of detoxification pathways. Int J Biochem Cell Biol. 2007; 39: 478-483. (Pubitemid 46096787)
16. Zhang B, Xie W, Krasowski MD,. PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics. 2008; 9: 1695-1709.
17. Wada T, Gao J, Xie W,. PXR and CAR in energy metabolism. Trends Endocrinol Metab. 2009; 20: 273-279.
18. Sinz M, Kim S, Zhu Z, et al. Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab. 2006; 7: 375-388.
19. Zhou J, Liu M, Zhai Y, et al. The antiapoptotic role of pregnane X receptor in human colon cancer cells. Mol Endocrinol. 2008; 22: 868-880. (Pubitemid 351482823)
20. Zimmermann C, van Waterschoot RA, Harmsen S, et al. PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009; 36: 565-571.
21. Lehmann JM, McKee DD, Watson MA, et al. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest. 1998; 102: 1016-1023. (Pubitemid 28419246)
22. Zhang W, Purchio A, Chen K, et al. In vivo activation of the human CYP3A4 promoter in mouse liver and regulation by pregnane X receptors. Biochem Pharmacol. 2003; 65: 1889-1896. (Pubitemid 36629514)
23. Liu Y, Ji W, Yin Y, et al. The effects of splicing variant of PXR PAR-2 on CYP3A4 and MDR1 mRNA expressions. Clin Chim Acta. 2009; 403: 142-144.
24. Cheng X, Klaassen CD,. Regulation of mRNA expression of xenobiotic transporters by the pregnane x receptor in mouse liver, kidney, and intestine. Drug Metab Dispos. 2006; 34: 1863-1867. (Pubitemid 44771714)
25. Shah YM, Ma X, Morimura K, et al. Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target gene expression. Am J Physiol Gastrointest Liver Physiol. 2007; 292: G1114-1122. (Pubitemid 46557773)
26. Dring MM, Goulding CA, Trimble VI, et al. The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology. 2006; 130: 341-348; quiz 592. (Pubitemid 43202034)
27. Ho GT, Soranzo N, Tate SK, et al. Lack of association of the pregnane X receptor (PXR/NR1I2) gene with inflammatory bowel disease: parallel allelic association study and gene wide haplotype analysis. Gut. 2006; 55: 1676-1677. (Pubitemid 44629238)
28. Amre DK, Mack DR, Israel D, et al. Investigation of associations between the pregnane-X receptor gene (NR1I2) and Crohn's disease in Canadian children using a gene-wide haplotype-based approach. Inflamm Bowel Dis. 2008; 14: 1214-1218.
29. Lacher M, Kappler R, Schroepf S, et al. Nuclear pregnane X receptor single nucleotide polymorphism (-25385C/T) is not associated with inflammatory bowel disease in pediatric patients. J Pediatr Gastroenterol Nutr. 2009; 49: 147-150.
30. Martinez A, Marquez A, Mendoza J, et al. Role of the PXR gene locus in inflammatory bowel diseases. Inflamm Bowel Dis. 2007; 13: 1484-1487.
31. Lennard-Jones JE,. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989; 170: 2-6; discussion 16-19. (Pubitemid 20015811)
32. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 (suppl A): 5-36.
33. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008; 40: 955-962.
34. Maier A, Zimmermann C, Beglinger C, et al. Effects of budesonide on P-glycoprotein expression in intestinal cell lines. Br J Pharmacol. 2007; 150: 361-368. (Pubitemid 46221044)
35. Ma X, Shah YM, Guo GL, et al. Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther. 2007; 322: 391-398. (Pubitemid 46956365)
36. Shafran I, Burgunder P,. Rifaximin for the treatment of newly diagnosed Crohn's disease: a case series. Am J Gastroenterol. 2008; 103: 2158-2160.
37. Shafran I, Johnson LK,. An open-label evaluation of rifaximin in the treatment of active Crohn's disease. Curr Med Res Opin. 2005; 21: 1165-1169. (Pubitemid 41140719)
38. Guslandi M, Petrone MC, Testoni PA,. Rifaximin for active ulcerative colitis. Inflamm Bowel Dis. 2006; 12: 335.
39. Nones K, Dommels YE, Martell S, et al. The effects of dietary curcumin and rutin on colonic inflammation and gene expression in multidrug resistance gene-deficient (mdr1a-/-) mice, a model of inflammatory bowel diseases. Br J Nutr. 2009; 101: 169-181.
40. Parkes M, McGovern DP, Frank A, et al. 18 new Crohn's disease susceptibility genes and loci identified by the International IBD Genetics Consortium. Gastroenterology. 2010; 138 (5 suppl 1): S115.
41. (downloaded 9/6/2010).
42. Park JH, Wacholder S, Gail MH, et al. Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet. 2010; 42: 570-575.